The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Cuomo, Ornella ^a   Rispoli, Vincenzo ^b   Leo, Antonio ^b   Politi, Giovanni Bosco ^b   Vinciguerra, Antonio ^a   Di Renzo, Gianfranco ^a   Cataldi, Mauro ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; ELECTROENCEPHALOGRAM; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; RAT; SEIZURE; SPIKE WAVE; WAVEFORM;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NEUROPROTECTIVE AGENTS; PIRACETAM; RATS; SEIZURES; TIME FACTORS;

EID: 84891803534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080852     Document Type: Article

References (50)

1. Crepeau AZ, Treiman DM (2010) Levetiracetam: a comprehensive review. Expert Rev Neurother 10: 159-171. doi:10.1586/ern.10.3. PubMed: 20136375.
2. Löscher W, Hönack D, Rundfeldt C (1998) Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 284: 474-479. PubMed: 9454787.
3. Stratton SC, Large CH, Cox B, Davies G, Hagan RM (2003) Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res 53: 95-106. doi:10.1016/S0920-1211(02)00254-1. PubMed: 12576171.
4. Vinogradova LV, van Rijn CM (2008) Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia 49: 1160-1168. doi:10.1111/j.1528-1167.2008.01594.x. PubMed: 18397292.
5. Russo E, Citraro R, Scicchitano F, De Fazio S, Di Paola ED et al. (2010) Comparison of the antiepileptogenic effects of an early longterm treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia 51: 1560-1569. PubMed: 19919665.
6. Russo E, Citraro R, Scicchitano F, De Fazio S, Perrotta I et al. (2011) Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 52: 1341-1350. doi:10.1111/j.1528-1167.2011.03112.x. PubMed: 21635238.
7. Marini H, Costa C, Passaniti M, Esposito M, Campo GM et al. (2004) Levetiracetam protects against kainic acid-induced toxicity. Life Sci 74: 1253-1264. doi:10.1016/j.lfs.2003.08.006. PubMed: 14697408.
8. Hanon E, Klitgaard H (2001) Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 10: 287-293. doi:10.1053/seiz.2000. 0511. PubMed: 11466025.
9. Kilicdag H, Daglioglu K, Erdogan S, Guzel A, Sencar L et al. (2012) The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Early Hum Dev 89: 355-360. PubMed: 23266150.
10. Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H et al. (2006) Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 5: 71-78. doi:10.1385/NCC:5:1:71. PubMed: 16960300.
11. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM et al. (2003) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U-S-A 26: 9861-9866. PubMed: 15210974.
12. Meehan AL, Yang X, Yuan LL, Rothman SM (2012) Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia 53: 469-476. doi:10.1111/j.1528-1167.2011.03392.x. PubMed: 22292611.
13. i increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther 313: 720-730. PubMed: 15644427.
14. 2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport 14: 471-475. PubMed: 12634506.
15. Nagarkatti N, Deshpande LS, DeLorenzo RJ (2008) Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci Lett 436: 289-293. doi:10.1016/j. neulet.2008.02.076. PubMed: 18406528.
16. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S et al. (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136: 659-672. doi:10.1038/sj.bjp.0704766. PubMed: 12086975.
17. Lukyanetz EA, Shkryl VM, Kostyuk PG (2002) Selective blockade of Ntype calcium channels by levetiracetam. Epilepsia 43: 9-18. doi: 10.1046/j.1528-1157. 43.s.9.4.x. PubMed: 11879381.
18. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M et al. (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45: 737-744. doi:10.1111/j.0013-9580.2004.00104.x. PubMed: 15230695.
19. Belcastro V, Pierguidi L, Tambasco N (2011) Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain Dev 33: 289-293. doi:10.1016/j.braindev.2010.06.008. PubMed: 20630672.
20. Rekling JC (2003) Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett 335: 167-170. doi:10.1016/S0304-3940(02)01193-X. PubMed: 12531459.
21. 2+ channels in neurovascular disorders and neurodegenerative diseases. Curr Neuropharmacol 11: 276-297. doi: 10.2174/1570159X11311030004. PubMed: 24179464.
22. Williams AJ, Tortella FC, Lu XM, Moreton JE, Hartings JA (2004) Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia. J Pharmacol Exp Ther 311: 220-227. doi:10.1124/jpet.104. 069146. PubMed: 15140918.
23. Nakamura H, Strong AJ, Dohmen C, Sakowitz OW, Vollmar S et al. (2010) Spreading depolarizations cycle around and enlarge focal ischaemic brain lesions. Brain 133: 1994-2006. doi:10.1093/brain/awq117. PubMed: 20504874.
24. Dreier JP, Major S, Pannek HW, Woitzik J, Scheel M et al. (2012) Spreading convulsions, spreading depolarization and epileptogenesis in human cerebral cortex. Brain 135: 259-275. doi:10.1093/brain/awr303. PubMed: 22120143.
25. Hartings JA, Williams AJ, Tortella FC (2003) Occurrence of nonconvulsive seizures, periodic epileptiform discharges, and intermittent rhythmic delta activity in rat focal ischemia. Exp Neurol 179: 139-149. doi:10.1016/S0014- 4886(02)00013-4. PubMed: 12618120.
26. Cuomo O, Gala R, Pignataro G, Boscia F, Secondo A et al. (2008) A critical role for the potassium-dependent sodium/calcium exchanger NCKX2 in protection against focal ischemic brain damage. J Neurosci 28: 2053-2063. doi:10.1111/j.1460-9568.2008.06502.x. PubMed: 18305240.
27. Cuomo O, Pignataro G, Gala R, Scorziello A, Gravino E et al. (2007) Antithrombin reduces ischemic volume, ameliorates neurologic deficits, and prolongs animal survival in both transient and permanent focal ischemia. Stroke 38: 3272-3279. doi:10.1161/STROKEAHA. 107.488486. PubMed: 17975103.
28. Clark WM, Lessov NS, Dixon MP, Eckenstein F (1997) Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol Res 19: 641-648. PubMed: 9427967.
29. Pignataro G, Boscia F, Esposito E, Sirabella R, Cuomo O et al. (2012) NCX1 and NCX3: two new effectors of delayed preconditioning in brain ischemia. Neurobiol Dis 45: 616-623. doi:10.1016/j.nbd.2011.10.007. PubMed: 22036625.
30. Leaõ AAP (1947) Further observation on the spreading depression of activity in the cerebral cortex. J Neurophysiol 10: 409-414. PubMed: 20268874.
31. Lu XC, Williams AJ, Tortella FC (2001) Quantitative electroencephalography spectral analysis and topographic mapping in a rat model of middle cerebral artery occlusion. Neuropathol Appl Neurobiol 27: 481-495. doi:10.1046/j.1365-2990.2001.00357.x. PubMed: 11903931.
32. Fleidervish IA, Gebhardt C, Astman N, Gutnick MJ, Heinemann U (2001) Enhanced spontaneous transmitter release is the earliest consequence of neocortical hypoxia that can explain the disruption of normal circuit function. J Neurosci 21: 4600-4608. PubMed: 11425888.
33. Canals S, Larrosa B, Pintor J, Mena MA, Herreras O (2008) Metabolic challenge to glia activates an adenosine-mediated safety mechanism that promotes neuronal survival by delaying the onset of spreading depression waves. J Cereb Blood Flow Metab 28: 1835-1844. doi: 10.1038/jcbfm.2008.71. PubMed: 18612316.
34. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN (1999) Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 34: 161-168. doi:10.1016/S0920-1211(98)00104-1. PubMed: 10210031.
35. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM (2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26: 1303-1313. doi:10.1523/JNEUROSCI.2699-05.2006. PubMed: 16436618.
36. 2+-induced exocytosis. J Neurosci 29: 883-897. doi: 10.1523/JNEUROSCI.4521-08.2009. PubMed: 19176798.
37. Yao J, Nowack A, Kensel-Hammes P, Gardner RG, Bajjalieh SM (2010) Cotrafficking of SV2 and synaptotagmin at the synapse. J Neurosci 30: 5569-5578. doi:10.1523/JNEUROSCI.4781-09.2010. PubMed: 20410110.
38. Fukuyama K, Tanahashi S, Nakagawa M, Yamamura S, Motomura E et al. (2012) Levetiracetam inhibits neurotransmitter release associated with CICR. Neurosci Lett 518: 69-74. doi:10.1016/j.neulet.2012.03.056. PubMed: 22484014.
39. Gill R, Andiné P, Hillered L, Persson L, Hagberg H (1992) The effect of MK-801 on cortical spreading depression in the penumbral zone following focal ischaemia in the rat. J Cereb Blood Flow Metab 12: 371-319. doi:10.1038/jcbfm.1992.54. PubMed: 1314840.
40. Eikermann-Haerter K, Lee JH, Yuzawa I, Liu CH, Zhou Z et al. (2012) Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations. Circulation 125: 335-345. doi:10.1161/ CIRCULATIONAHA.111. 045096. PubMed: 22144569.
41. Müller M, Somjen GG (1998) Inhibition of major cationic inward currents prevents spreading depression-like depolarization in rat hippocampal tissue slices. Brain Res 812: 1-13. doi:10.1016/S0006-8993(98)00812-9. PubMed: 9813218.
42. Leker RR, Neufeld MY (2003) Anti-epileptic drugs as possible neuroprotectants in cerebral ischemia. Brain. Res Rev 42: 187-203. doi:10.1016/S0165-0173(03)00170-X.
43. Costa C, Martella G, Picconi B, Prosperetti C, Pisani A et al. (2006) Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 37: 1319-1326. doi: 10.1161/01.STR. 0000217303.22856.38. PubMed: 16574927.
44. Margineanu DG, Klitgaard H (2009) Brivaracetam inhibits spreading depression in rat neocortical slices in vitro. Seizure 18: 453-456. doi: 10.1016/j.seizure.2009.01.002. PubMed: 19211275.
45. Meehan AL, Yang X, McAdams BD, Yuan L, Rothman SM (2011) A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol 106: 1227-1239. doi:10.1152/jn.00279.2011. PubMed: 21653714.
46. Williams AJ, Bautista CC, Chen RW, Dave JR, Lu XC et al. (2006) Evaluation of gabapentin and ethosuximide for treatment of acute nonconvulsive seizures following ischemic brain injury in rats. J Pharmacol Exp Ther 318: 947-955. doi:10.1124/jpet.106.105999. PubMed: 16728590.
47. Burn J, Dennis M, Bamford J, Sandercock P, Wade D et al. (1997) Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ 315: 1582-1587. doi:10.1136/bmj.315.7122.1582. PubMed: 9437276.
48. Camilo O, Goldstein LB (2004) Seizures and epilepsy after ischaemic stroke. Stroke 35: 1769-1775. doi:10.1161/01.STR. 0000130989.17100.96. PubMed: 15166395.
49. Herman ST (2002) Epilepsy after brain insult: targeting epileptogenesis. Neurology 59 (Suppl 5): S21-S26. doi:10.1212/WNL.59.4.21A. PubMed: 12428028.
50. Williams AJ, Tortella FC, Gryder D, Hartings JA (2008) Topiramate reduces non-convulsive seizures after focal brain ischemia in the rat. Neurosci Lett 430: 7-12. doi:10.1016/j.neulet.2007.09.052. PubMed: 18063309.